Advertisement

LNP Technology for Non-Viral Delivery of Nucleic Acids

Empower contract research with Invitrogen’s advanced LNP portfolio

by | Dec 13, 2024

For contract laboratories supporting cutting-edge genetic medicine research, Invitrogen Vivofectamine™ Delivery Solutions offer the perfect non-viral delivery technology. Backed by decades of expertise, this LNP enhances the delivery of nucleic acids for gene therapies, cancer vaccines, and stem cell applications.

Why contract labs choose this LNP portfolio

  • Enhanced Client Offerings: Enable researchers to adopt safer, non-viral alternatives.
  • Flexible Licensing: Customizable terms and formulations meet varied client needs.
  • Proven Results: Extensive validation in systemic, intramuscular, and localized delivery.
  • Cost and Time Efficiency: Streamlined processes reduce turnaround time for client projects.

Thermo Fisher’s Vivofectamine Delivery Solutions allow contract labs to elevate their service portfolios, delivering tailored results to meet the evolving needs of genetic medicine clients.

This article has been sourced from a press release and may include content created or refined using AI tools and verified by our editorial team. For the full press release, visit: Thermo Fisher Scientific

Author

Related Content

Advertisement

Editor's Choice

Advertisement

Advertisement